Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease

Alimentary Pharmacology and Therapeutics

Volumn 45, Issue 4, 2017, Pages 510-518

  Petta, S ^a   Ciminnisi, S ^a   Di Marco, V ^a   Cabibi, D ^a   Camma C ^a   Licata, A ^a   Marchesini, G ^b   Craxi A ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERTENSION; IMPEDANCE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MUSCLE MASS; MUSCULOSKELETAL SYSTEM PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SARCOPENIA; SKELETAL MUSCLE MASS INDEX; AGED; BLOOD; CROSS-SECTIONAL STUDY; INSULIN RESISTANCE; LIVER CIRRHOSIS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PHYSIOLOGY; PROSPECTIVE STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PROSPECTIVE STUDIES; RISK FACTORS; SARCOPENIA; SEVERITY OF ILLNESS INDEX;

EID: 85007507425     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13889     Document Type: Article

References (42)

1. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44–52.
2. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547–54.
3. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149: 389–97.e10.
4. Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009; 41: 615–25.
5. Targher G, Bertolini L, Scala L, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007; 17: 517–24.
6. Petta S, Cammà C, Cabibi D, Di Marco V, Craxì A. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 34: 757–66.
7. Abdelmalek MF, Suzuki A, Guy C, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Increased fructose consumption is associated with fibrosis severity in patients with non-alcoholic fatty liver disease. Hepatology 2010; 51: 1961–71.
8. Turola E, Petta S, Vanni E, et al. Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. Dis Model Mech 2015; 8: 1037–46.
9. Cruz-Jentoft AJ, Landi F, Topinkova E, Michel JP. Understanding sarcopenia as a geriatric syndrome. Curr Opin Clin Nutr Metab Care 2010; 13: 1–7.
10. The Lancet Diabetes Endocrinology. Sarcopenia: a fate worth challenging. Lancet Diabetes Endocrinol 2014; 2: 183.
11. Lee YH, Jung KS, Kim SU, et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). J Hepatol 2015; 63: 486–93.
12. Hong HC, Hwang SY, Choi HY, et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology 2014; 59: 1772–8.
13. Koo BK, Kim D, Joo SK, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol 2016; doi:10.1016/j.jhep.2016.08.019 [Epub ahead of print]
14. Montano-Loza AJ, Duarte-Rojo A, Meza-Junco J, et al. Inclusion of sarcopenia within MELD (MELD-Sarcopenia) and the prediction of mortality in patients with cirrhosis. Clin Transl Gastroenterol 2015; 16: e102.
15. Kalafateli M, Konstantakis C, Thomopoulos K, Triantos C. Impact of muscle wasting on survival in patients with liver cirrhosis. World J Gastroenterol 2015; 21: 7357–61.
16. Hanai T, Shiraki M, Nishimura K, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition 2015; 31: 193–9.
17. Alberti KG, Eckel RH, Grundy SM, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640–5.
18. American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. American Diabetes Association: Clinical Practice Recommendations 2000 Committee Report. Diabetes Care 2000; 23: S4–19.
19. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–9.
20. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239–44.
21. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 411: 313–21.
22. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002; 50: 889–96.
23. Baumgartner RN, Chumlea WC, Roche AF. Bioelectric impedance phase angle and body composition. Am J Clin Nutr 1988; 48: 16–23.
24. Selberg O, Selberg D. Norms and correlates of bioimpedance phase angle in healthy human subjects, hospitalized patients, and patients with liver cirrhosis. Eur J Appl Physiol 2002; 86: 509–16.
25. Frontera WR, Hughes VA, Fielding RA, Fiatarone MA, Evans WJ, Roubenoff R. Aging of skeletal muscle: a 12–yr longitudinal study. J Appl Physiol 2000; 88: 1321–6.
26. Sartiani L, Spinelli V, Laurino A, et al. Pharmacological perspectives in sarcopenia: a potential role for renin-angiotensin system blockers? Clin Cases Miner Bone Metab 2015; 12: 135–8.
27. Zhou LS, Xu LJ, Wang XQ, Huang YH, Xiao Q. Effect of angiotensin-converting enzyme inhibitors on physical function in elderly subjects: a systematic review and meta-analysis. Drugs Aging 2015; 32: 727–35.
28. Witham MD, Syddall HE, Dennison E, Cooper C, McMurdo ME, Sayer AA. ACE inhibitors, statins and thiazides: no association with change in grip strength among community dwelling older men and women from the Hertfordshire Cohort Study. Age Ageing 2014; 43: 661–6.
29. Cetrone M, Mele A, Tricarico D. Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II. Curr Diabetes Rev 2014; 10: 231–7.
30. Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology 2014; 147: 577–94.
31. Hribal ML, Procopio T, Petta S, et al. Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2013; 98: E304–8.
32. Miller AM, Wang H, Bertola A, et al. Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice. Hepatology 2011; 54: 846–56.
33. Bostrom P, Wu J, Jedrychowski MP, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463–8.
34. Englesbe MJ, Patel SP, He K, et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg 2010; 211: 271–8.
35. Guida B, Trio R, Pecoraro P, et al. Impedance vector distribution by body mass index and conventional bioelectrical impedance analysis in obese women. Nutr Metab Cardiovasc Dis 2003; 13: 72–9.
36. Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012; 10: 166–73.
37. Marini E, Buffa R, Saragat B, et al. The potential of classic and specific bioelectrical impedance vector analysis for the assessment of sarcopenia and sarcopenic obesity. Clin Interv Aging 2012; 7: 585–91.
38. Marini E, Sergi G, Succa V, et al. Efficacy of specific bioelectrical impedance vector analysis (BIVA) for assessing body composition in the elderly. J Nutr Health Aging 2013; 17: 515–21.
39. Buffa R, Saragat B, Cabras S, Rinaldi AC, Marini E. Accuracy of specific BIVA for the assessment of body composition in the United States population. PLoS ONE 2013; 8: e58533.
40. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the european working group on sarcopenia in older people. Age Ageing 2010; 39: 412–23.
41. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 2011; 12: 249–56.
42. Dasarathy S, Merli M. Sarcopenia: from mechanism to diagnosis and treatment in liver disease. J Hepatol 2016; 65: 1232–44.